focus -WSS

focus

author：leisure time 2025-10-01 00:46:45 - browse：1977

Sage Therapeutics, a biotech developing an experimental treatment for postpartum depression, this week trumpeted strong results from a clinical trial, which cheered investors and pushed up its stock price. But outside the lab, the company’s aggressive efforts to raise awareness of postpartum depression have proved divisive.

The campaign’s message: “When it comes to postpartum depression, silence sucks.” It features close-up photos of distressed, tearful women who can’t speak — because they have pacifiers stuck in their mouths.

The images have been plastered on bus stops, buses, conference booths, and on a dedicated website. The ads don’t specifically mention Sage’s drug, which still needs further testing before the company can bring it to the Food and Drug Administration for possible approval. Instead, they urge women to talk “openly and honestly” about postpartum depression. An estimated 600,000 women in the U.S. alone experience symptoms, which range from insomnia and irritability to difficulty bonding with their baby.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： How to ethically and practically extend health care to all

knowledge

WSS

Florida officials tell state schools to teach AP Psychology 'in its entirety'

New chart reveals military’s vast involvement in Operation Warp Speed

Hey, doctors: Don't be no

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

Late stage cancers on the rise after pandemic delayed screenings

A new deal aims to ramp up use of AI in rehab care decisions

focus

focus

entertainment

Hepatitis C has a cure — but many Americans still lack access to it

When waiting feels immoral: Empathy in the emergency department

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Pfizer's RSV vaccine recommended for approval in Europe

Hepatitis C has a cure — but many Americans still lack access to it

Pfizer's RSV vaccine recommended for approval in Europe

United colonoscopy coverage change 'may cost lives,' doctors say

What is artificial intelligence? Experts weigh in

Affirmative action in medical school literally saved lives

'Null' research findings aren't empty of meaning. Let's publish them

knowledge

Late stage cancers on the rise after pandemic delayed screenings

Group behind ProMed defends move to subscription

The biotech scorecard for the 2nd quarter: 12 industry events to watch

Grand jury probing Trump's efforts to overturn 2020 election did not meet Friday: Sources

Listen: BridgeBio's big week & Lilly's Alzheimer's data

Flint parents haunted by uncertainty, fears of lead poisoning

entertainment

knowledge

hotspot

entertainment